AstraZeneca shares plunge around 9.5% as late-stage heart drug trial fails

Traders Union
All News
Financial News
Astrazeneca slides 9.59% to GBX12874

Highlights

AstraZeneca shares declined sharply after a late-stage trial failure in heart disease and early termination of the HELIOS study.
Additional negative sentiment stemmed from major co-development deals—including a $2.1 billion agreement with Sino Biopharmaceutical—and insider share allocations.
Technicals show AstraZeneca trades below key averages with strong downward momentum; probability of further decline toward GBX11,074 is 68% over five days.

Broader pipeline concerns as licensing moves amplify negative sentiment

AstraZeneca reported a significant setback after the failure of a late-stage clinical trial for a heart disease treatment. Additional downward pressure followed announcements of major licensing and co-development agreements, including a global license for TQC3721, a collaboration with Helix, and a deal with Sino Biopharmaceutical valued up to $2.1 billion. The early termination of the HELIOS study and an NHS access expansion agreement for Enhertu with Daiichi Sankyo were also disclosed, along with insider share allocations under the company's incentive plan.

Anton Kharitonov, expert at Traders Union, sees AstraZeneca in a clear technical and sentiment-driven downtrend. He notes momentum is weak across all key moving averages with strong selling pressure. Kharitonov highlights that the clinical trial failure and heavy trading losses undermine confidence in the company’s pipeline, intensifying risk. He observes conflicting technical signals, but skepticism is warranted with volatility high and buyers only tentatively returning mid-session. "Near-term downside risk dominates — until AstraZeneca breaks above at least GBX13,107, I view any recovery as fragile."

Viktoras Karapetjanc, expert at Traders Union, points to AstraZeneca's robust strategic moves, including several global licensing agreements and a major partnership with Sino Biopharmaceutical. He believes these initiatives broaden the company’s growth platform beyond the recent clinical setback. Karapetjanc sees opportunity for a technical rebound, as oversold readings from the RSI and CCI suggest buyers are poised to re-enter. "Current market volatility creates setups for further upside — I expect AstraZeneca to leverage its global expansion for renewed strength above GBX13,107."

Mixed technical momentum amid strong resistance and intraday buyer interest

AstraZeneca is trading below its 20-day (GBX13,821), 50-day (GBX13,731), and 200-day (GBX13,768) moving averages, indicating a loss of momentum across short-, medium-, and long-term trends. The current structure points to persistent selling pressure, with the near-term ceiling marked at GBX13,107 and the immediate floor at GBX12,388. Momentum remains mixed: the Moving Average Convergence Divergence (MACD) signals a buy, suggesting attempts at recovery, but the Average Directional Index (ADX) issues a sell, indicating that the prevailing downward trend remains strong. The Relative Strength Index (RSI) and Commodity Channel Index (CCI) both rate the stock as a buy, suggesting oversold conditions may be developing, but the Stochastic RSI and Hull Moving Average (HMA) both point to selling. Bull/Bear Power (BBP) is firmly positive, indicating buyers are dominating intraday action, but it is already in overbought territory. The Awesome Oscillator (AO) is neutral, adding little conviction either way. AstraZeneca gapped sharply lower at the open, falling by GBX1,366 or 9.59%, and has since traded near the top of today’s range. Intraday volatility is elevated at 5.81%. There are contrasting signals: strong downward pressure after the opening gap, yet indications of buyers returning into midday trading.

Previously it was reported that AstraZeneca faced sustained bearish momentum after a pivotal clinical trial failure fueled heightened selling pressure and uncertainty. With the latest technical signals indicating a mixture of oversold conditions and persistent downside risk, traders should monitor GBX12,388 as the nearest support level for signs of either stabilization or an accelerated decline toward GBX11,074.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.